Clinical Trial: Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

Study Status: Available
Recruit Status: Available
Study Type: Expanded Access

Official Title: Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

Brief Summary: The purpose of the study is to provide expanded access (compassionate use) of 3,4 diaminopyridine to patients with Lambert-Eaton myasthenic syndrome (LEMS).

Detailed Summary:

Up to 15 patients over the age of 18 years with a diagnosis of LEMS are eligible to enroll if they are medically stable. They may receive 3,4 diaminopyridine in addition to other treatments and standard of care investigations for LEMS under supervision of the primary investigator. Safety laboratory studies and EKGs will be obtained.

The study has been approved by the University of Pittsburgh IRB. There is a local Data-Safety Monitoring Board.

Sponsor: University of Pittsburgh

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of Pittsburgh

Dates:
Date Received: October 8, 2009
Date Started:
Date Completion:
Last Updated: May 4, 2017
Last Verified: May 2017